Document Detail

Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein.
MedLine Citation:
PMID:  23013513     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Statins decrease cardiovascular events mainly by lowering cholesterol but anti-inflammatory effects also play a role. The effects of the cholesterol absorption inhibitor ezetimibe on markers of inflammation remain unclear. We performed an exploratory post-hoc analysis whether these drugs influence the pro-inflammatory markers interleukin-6 and high-sensitivity C-reactive protein in subjects with very-low cardiovascular risk.
DESIGN: Single center, randomized, parallel 3-group study in 72 healthy men without apparent cardiovascular disease (age 32 ± 9 years, BMI 25.7 ± 3.2 kg/m(2)). Each group of 24 subjects received a 14-day treatment with either simvastatin 40 mg, ezetimibe 10 mg, or their combination.
RESULTS: Baseline IL-6 and hsCRP concentrations in the total cohort were 0.72 ± 0.57 ng/l and 0.40 ± 0.65 mg/l, respectively, with no differences between the 3 groups. Median changes (interquartile range) in IL-6 and hsCRP concentrations were -22% (-43 to 0%) and -30% (-44 to +19%) after simvastatin, -5% (-36 to +30%) and +9% (-22 to +107%) after ezetimibe, and +15% (-15 to +86%) and +1 (-30 to +49%) after the combination. Using a generalized linear model, the multivariable adjusted overall P-values for these changes were 0.008 (IL-6) and 0.1 (hsCRP).
CONCLUSIONS: Simvastatin decreases the pro-inflammatory markers IL-6 and almost significantly hsCRP while ezetimibe monotherapy or the combination with simvastatin has no effect.
Heiner K Berthold; Kaspar Berneis; Christos S Mantzoros; Wilhelm Krone; Ioanna Gouni-Berthold
Related Documents :
6602133 - Effects of radiation on murine t-cell leukemogenesis induced by butylnitrosourea.
14643953 - Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fr...
6974143 - Misonidazole enhancement of radiation-induced growth delay in rat rhabdomyosarcoma tumo...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-10-18
Journal Detail:
Title:  Scandinavian cardiovascular journal. Supplement     Volume:  47     ISSN:  1651-2510     ISO Abbreviation:  Scand Cardiovasc J Suppl     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-17     Completed Date:  2013-07-02     Revised Date:  2013-08-14    
Medline Journal Info:
Nlm Unique ID:  9711058     Medline TA:  Scand Cardiovasc J Suppl     Country:  England    
Other Details:
Languages:  eng     Pagination:  20-7     Citation Subset:  IM    
Charité University Medicine Berlin, Evangelical Geriatrics Center Berlin (EGZB), Berlin, Germany.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / administration & dosage*
Anticholesteremic Agents / administration & dosage*
Azetidines / administration & dosage*
Biological Markers / blood
C-Reactive Protein / metabolism*
Drug Administration Schedule
Drug Combinations
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Inflammation Mediators / blood*
Interleukin-6 / blood*
Linear Models
Middle Aged
Multivariate Analysis
Prospective Studies
Simvastatin / administration & dosage*
Time Factors
Young Adult
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Anticholesteremic Agents; 0/Azetidines; 0/Biological Markers; 0/Drug Combinations; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/IL6 protein, human; 0/Inflammation Mediators; 0/Interleukin-6; 0/ezetimibe, simvastatin drug combination; 163222-33-1/ezetimibe; 79902-63-9/Simvastatin; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Control of amyloid assembly by autoregulation.
Next Document:  Treatment of prurigo nodularis with pregabalin.